KIR3DL2/CD158k Antibody (539304) [Alexa Fluor® 647]

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

KIR3DL2 (3DL2, p140, CD158k) is a type I transmembrane protein of the p70 family of killer cell Ig-like receptors (KIR). KIR are expressed on CD56^dim NK cells and T cell subsets where they participate in identifying normal and abnormal cells and regulating effector functions of the innate immune system (1-4). KIR are named for the number of Ig-like domains (2D or 3D) in the extracellular domain (ECD) and whether they have long or short (L, S) cytoplasmic tails. Like other inhibitory KIR, KIR3DL2 has two ITIM domains within its long tail (3). KIR3DL2 is diverse, with twelve alleles identified and as many as five single amino acid polymorphisms found in a single individual (4-6). Unlike most other KIR, gene transcripts of KIR3DL2 are expressed by all individuals (4). KIR3DL2 is present on the cell surface as a disulfide-linked homodimer of 70 kDa, 434 aa subunits (4). KIR3DL2 has shown peptide-specific binding to some HLA-A antigens, including A3 and A11 (4, 7, 8).  It also binds the abnormally folded HLA-B27 homodimer found in spondylarthritides, but not the normal heterodimer of HLA-B27 with beta 2‑microglobulin (9, 10). NK and CD4⁺ T cells from patients with spondylarthritides show increased KIR3DL2⁺ expression and may play a role in disease pathology (10). KIR3DL2 is also a marker for atypical mononuclear (Sezary) cells in the blood of patients with Sezary syndrome, an erythrodermic form of cutaneous T cell lymphoma (11). Human KIR3DL2 ECD shows 88-92% aa identity to KIR3DL2 of other primates. KIR receptors have no structural orthologs in non-primates, although mouse Ly-49 proteins are functional orthologs (3). KIR are highly related. The closest relative, KIR3DL1 shows 86% aa identity with KIR3DL2 within the ECD.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array FAB2878R

• KIR3DL2/CD158k Antibodies
• KIR3DL2/CD158k Lysate